Who was studied, and how
Four numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
6,058people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
PPAR agonist plus metformin
metformin alone
Lowered fasting blood sugar−22.1
Lowered long-term blood sugar−0.53
Lowered insulin resistance−1.26
randomisedthe abstract, start to end
… of fasting glucose [MD = - 22.07 mg/dl (95% CI - 27.17, - 16.97), HbA1c [MD = - 0.53% (95% CI - 0.67, - 0.38)], HOMA-IR [MD = - 1.26 (95% CI - 2.16, - 0.37)], and fasting insulin [MD = - 19.83 pmol/L (95% CI - 29.54, …
← favours treatmentfavours comparator →
could be chanceFasting glucosePPAR agonist plus metformin vs metformin alone
−22.1−27.2 to −17.0
HbA1cPPAR agonist plus metformin vs metformin alone
−0.53−0.67 to −0.38
HOMA-IRPPAR agonist plus metformin vs metformin alone
−1.26−2.16 to −0.37
Fasting insulinPPAR agonist plus metformin vs metformin alone
−19.8−29.5 to −10.1
MetforminGlycemic control
1 / 5